PARIS, February 26 /PRNewswire-FirstCall/ -- ExonHit Therapeutics
(Alternext: ALEHT) is pleased to announce that clinical testing of EHT 0202,
its lead compound in Alzheimer's disease, is progressing well.

READING, England, February 26 /PRNewswire/ --
- Intranasal Apomorphine for the Treatment of Motor Fluctuations in
Advanced Parkinson's Disease
- Intranasal Diazepam for the Treatment of Acute Repetitive Seizures in
Epilepsy
- Phase II Trials on Both Projects to be Initiated During 2009
Archimedes Pharma Limited, the pan-European specialty pharmaceutical
company, today announces positive headline data from its recently completed
proof-of-concept trials for two of its intranasal (IN) development projects.
Both the IN Apomorphine and IN Diazepam Phase I studies showed high
bioavailability, positive pharmacokinetics and good tolerability and
confirmed that each candidate has the potential to replace existing
formulations in high value markets.

A pivoted catch designed to fall into a notch on a ratchet wheel so as to allow movement in only one direction (e.g. on a windlass or in a clock mechanism), or alternatively to move the wheel in one direction.